CN1173975C - 咪唑并吡啶衍生物 - Google Patents
咪唑并吡啶衍生物 Download PDFInfo
- Publication number
- CN1173975C CN1173975C CNB018086551A CN01808655A CN1173975C CN 1173975 C CN1173975 C CN 1173975C CN B018086551 A CNB018086551 A CN B018086551A CN 01808655 A CN01808655 A CN 01808655A CN 1173975 C CN1173975 C CN 1173975C
- Authority
- CN
- China
- Prior art keywords
- alkyl group
- low
- low alkyl
- group
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Description
Co | X | Syn | Dat |
70 | S | 34 | N1:3.70(3H,s),4.29(2H,s),8.25(1H,s) |
136 | SO2 | 28 | N2:3.74(3H,s),4.35(2H,s),8.19(1H,d,J=9.6Hz) |
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000128295 | 2000-04-27 | ||
JP128295/2000 | 2000-04-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100474536A Division CN1308327C (zh) | 2000-04-27 | 2001-04-26 | 咪唑并吡啶衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1426413A CN1426413A (zh) | 2003-06-25 |
CN1173975C true CN1173975C (zh) | 2004-11-03 |
Family
ID=18637756
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100474536A Expired - Lifetime CN1308327C (zh) | 2000-04-27 | 2001-04-26 | 咪唑并吡啶衍生物 |
CNB018086551A Expired - Lifetime CN1173975C (zh) | 2000-04-27 | 2001-04-26 | 咪唑并吡啶衍生物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100474536A Expired - Lifetime CN1308327C (zh) | 2000-04-27 | 2001-04-26 | 咪唑并吡啶衍生物 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1277754B8 (zh) |
JP (1) | JP3729343B2 (zh) |
KR (1) | KR100830859B1 (zh) |
CN (2) | CN1308327C (zh) |
AT (1) | ATE300540T1 (zh) |
AU (1) | AU2001252609A1 (zh) |
CA (1) | CA2407573C (zh) |
DE (1) | DE60112272T2 (zh) |
DK (1) | DK1277754T3 (zh) |
ES (1) | ES2244613T3 (zh) |
WO (1) | WO2001083481A1 (zh) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100567D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
AU2002364889A1 (en) * | 2001-09-24 | 2003-06-10 | University Of Aarhus | Methods for diagnosis and treatment of diseases associated with altered expression of nrf2 |
DE60215864T2 (de) * | 2001-11-30 | 2007-05-31 | Qlt Inc., Vancouver | Behandlung von okularen neovaskularen erkrankungen |
WO2003074525A1 (fr) * | 2002-03-01 | 2003-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Compose heterocyclique azote |
WO2004017950A2 (en) * | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
WO2005023800A1 (en) * | 2003-09-04 | 2005-03-17 | Warner-Lambert Company Llc | Halo substituted benzo`b! thiophenes with pi3k inhibitory activity as therapeutic agents |
BRPI0506749A (pt) * | 2004-01-12 | 2007-05-22 | Applied Research Systems | derivados de tiazol e uso dos mesmos |
JP2008509987A (ja) * | 2004-08-18 | 2008-04-03 | ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー | トリアゾロピリジン化合物 |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
CA2583812A1 (en) * | 2004-10-28 | 2006-05-11 | Irm Llc | Compounds and compositions as hedgehog pathway modulators |
EP1813613B1 (en) | 2004-11-08 | 2012-12-19 | Msd K.K. | Novel fused imidazole derivative |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
CN101796056A (zh) * | 2006-09-18 | 2010-08-04 | 沃泰克斯药物股份有限公司 | c-MET的杂环抑制剂及其用途 |
EP1972631A1 (en) * | 2007-03-23 | 2008-09-24 | Novartis AG | Imidazopyridazines as PI3K lipid kinase inhibitors |
CA2667960A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
MX2009005478A (es) | 2006-11-27 | 2009-08-12 | Lundbeck & Co As H | Derivados de heteroarilamida. |
AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
CN101502484B (zh) * | 2006-12-26 | 2011-04-20 | 济南康泉医药科技有限公司 | 同载糖皮质激素和化疗药物的抗癌缓释剂 |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
MY156814A (en) | 2007-03-15 | 2016-03-31 | Novartis Ag | Organic compounds and their uses |
CN103214482B (zh) | 2007-04-03 | 2016-06-29 | 阵列生物制药公司 | 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物 |
CN103204852A (zh) | 2007-04-10 | 2013-07-17 | H.隆德贝克有限公司 | 作为p2x7拮抗剂的杂芳基酰胺类似物 |
JP2010524953A (ja) * | 2007-04-17 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤 |
AR066477A1 (es) * | 2007-05-09 | 2009-08-19 | Novartis Ag | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido |
JP5702138B2 (ja) * | 2007-05-18 | 2015-04-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 過剰増殖障害および血管新生に関連する疾患の処置に有用なヘテロアリール置換ピラゾール誘導体 |
UY31292A1 (es) * | 2007-08-14 | 2009-03-31 | Imidazoles biciclicos fusionados | |
EP2062893A1 (en) * | 2007-10-18 | 2009-05-27 | Bayer Schering Pharma AG | Fused imidazoles for cancer treatment |
JP5133416B2 (ja) | 2007-09-14 | 2013-01-30 | オルソー−マクニール−ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1’,3’−二置換−4−フェニル−3,4,5,6−テトラヒドロ−2h,1’h−[1,4’]ビピリジニル−2’−オン |
TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
AU2008328882A1 (en) * | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as PI3K inhibitors |
EP2240488B1 (en) | 2008-02-06 | 2016-11-02 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
AU2009218459A1 (en) | 2008-02-28 | 2009-09-03 | Novartis Ag | Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease |
WO2009126624A1 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
WO2009126861A2 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
US8134000B2 (en) | 2008-07-14 | 2012-03-13 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
KR20110038159A (ko) | 2008-07-28 | 2011-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
US8895550B2 (en) | 2008-08-19 | 2014-11-25 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
US8987251B2 (en) | 2008-08-19 | 2015-03-24 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
WO2010022081A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
WO2010074586A1 (en) * | 2008-12-23 | 2010-07-01 | Pathway Therapeutics Limited | Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy |
WO2010117926A1 (en) | 2009-04-07 | 2010-10-14 | Schering Corporation | Substituted triazolopyridines and analogs thereof |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
EP2430031B1 (en) | 2009-05-12 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MX2011013166A (es) | 2009-06-08 | 2012-01-30 | Gilead Sciences Inc | Compuestos inhibidores de hdac de cicloalquilcarbamatobenzamida-an ilina. |
WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EP2464649A1 (en) | 2009-08-12 | 2012-06-20 | Novartis AG | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
IN2012DN01453A (zh) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
EP2496578A4 (en) | 2009-11-05 | 2013-08-21 | Univ Notre Dame Du Lac | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF |
WO2011055320A1 (en) * | 2009-11-06 | 2011-05-12 | Piramal Life Sciences Limited | Imidazopyridine derivatives |
RU2619463C2 (ru) * | 2009-12-30 | 2017-05-16 | Аркьюл, Инк. | Замещенные имидазопиридинил-аминопиридиновые соединения, полезные при лечении рака |
US9145419B2 (en) | 2010-04-28 | 2015-09-29 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds |
TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
AU2011328195B2 (en) | 2010-11-08 | 2015-04-02 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
WO2012062750A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
US20120129872A1 (en) * | 2010-11-18 | 2012-05-24 | Kristi Anne Leonard | Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation |
JP5918264B2 (ja) | 2010-12-22 | 2016-05-18 | アッヴィ・インコーポレイテッド | C型肝炎阻害剤およびその使用 |
CN102030752A (zh) * | 2011-01-06 | 2011-04-27 | 贵阳中医学院 | 一种制备化合物2-(咪唑并[1,2-a]吡啶-3-基)乙腈的方法 |
TW201242965A (en) | 2011-02-01 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | Ring-fused heterocyclic derivative |
RS54586B1 (en) | 2011-02-25 | 2016-08-31 | Array Biopharma Inc. | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS |
PL2694510T3 (pl) | 2011-04-07 | 2016-03-31 | Bayer Ip Gmbh | Imidazopirydazyny jako inhibitory kinazy Akt |
WO2012156379A1 (en) * | 2011-05-13 | 2012-11-22 | Universität Zürich | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING |
KR101274986B1 (ko) * | 2011-07-27 | 2013-06-17 | 한국과학기술원 | 이미다조피리딘 유도체, 이를 포함하는 PI3K 및/또는 mTOR 저해제용 약학 조성물 및 PI3K 및/또는 mTOR과 연관된 질환 치료용 약학 조성물 |
TW201410677A (zh) | 2012-07-31 | 2014-03-16 | Kyowa Hakko Kirin Co Ltd | 縮環雜環化合物 |
US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
CA2891976C (en) * | 2012-11-30 | 2020-07-21 | Astellas Pharma Inc. | Imidazopyridine compounds |
CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
PL3431106T3 (pl) | 2014-01-21 | 2021-06-28 | Janssen Pharmaceutica Nv | Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
WO2015123408A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
CR20200362A (es) | 2014-02-13 | 2020-10-26 | Incyte Corp | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) |
US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
CN106459090A (zh) | 2014-02-19 | 2017-02-22 | 拜耳制药股份公司 | 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶 |
WO2015140199A1 (de) | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
CA2938923A1 (en) * | 2014-03-24 | 2015-10-01 | Arqule Inc. | Process of preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine |
WO2015164479A1 (en) * | 2014-04-22 | 2015-10-29 | Arqule, Inc. | Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound |
CA2947374A1 (en) | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
AP2017009744A0 (en) | 2014-08-06 | 2017-02-28 | Pfizer | Imidazopyridazine compounds |
JP2017536396A (ja) | 2014-12-02 | 2017-12-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | ヘテロアリール置換イミダゾ[1,2−a]ピリジンおよびその使用 |
CN107660205B (zh) | 2015-04-03 | 2021-08-27 | 因赛特公司 | 作为lsd1抑制剂的杂环化合物 |
EP3334709A1 (en) | 2015-08-12 | 2018-06-20 | Incyte Corporation | Salts of an lsd1 inhibitor |
JP7055378B2 (ja) | 2015-09-17 | 2022-04-18 | ユニバーシティ・オブ・ノートル・ダム・デュ・ラック | マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物 |
GB201602527D0 (en) * | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
WO2017181973A1 (zh) * | 2016-04-20 | 2017-10-26 | 苏州苏领生物医药有限公司 | 五元杂环类化合物及其制备方法、药物组合物和用途 |
CN107304202A (zh) * | 2016-04-20 | 2017-10-31 | 苏州苏领生物医药有限公司 | 五元杂环类化合物及其制备方法、药物组合物和用途 |
PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
EP3454852A4 (en) | 2016-05-11 | 2020-02-26 | Emory University | Phosphatidylinositol-3-Kinase Inhibitors |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
MX2020004190A (es) | 2017-10-24 | 2020-08-03 | Bayer Ag | Amidas de imidazopiridina sustituidas y su uso. |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
EP3941587A1 (en) | 2019-03-19 | 2022-01-26 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
TW202206409A (zh) * | 2020-04-27 | 2022-02-16 | 南韓商奧士擇破利悟股份有限公司 | 用於ubr盒結構域配體之化合物以及醫藥組成物 |
CA3183100A1 (en) | 2020-05-29 | 2021-12-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anthelmintic heterocyclic compounds |
CN113135913B (zh) * | 2021-04-28 | 2022-05-24 | 沈阳药科大学 | 3-取代基-6-吡啶类取代基-六元并五元杂环类衍生物及其制法与用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4735956A (en) | 1985-09-13 | 1988-04-05 | Merck & Co., Inc. | Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers |
JP2782823B2 (ja) * | 1989-08-21 | 1998-08-06 | 吉富製薬株式会社 | ニコチン酸アミド化合物 |
IL96432A0 (en) * | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
JPH11505524A (ja) * | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ1,2−aピリジンおよびイミダゾ1,2−aピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
GB9927687D0 (en) * | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
ATE414079T1 (de) * | 2000-03-01 | 2008-11-15 | Janssen Pharmaceutica Nv | 2,4-disubstituierte thiazolyl derivate |
DE10038019A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
AU2001295992A1 (en) * | 2000-10-24 | 2002-05-06 | Sankyo Company Limited | Imidazopyridine derivatives |
-
2001
- 2001-04-26 KR KR1020027014389A patent/KR100830859B1/ko active IP Right Grant
- 2001-04-26 DK DK01925980T patent/DK1277754T3/da active
- 2001-04-26 AT AT01925980T patent/ATE300540T1/de not_active IP Right Cessation
- 2001-04-26 CN CNB2004100474536A patent/CN1308327C/zh not_active Expired - Lifetime
- 2001-04-26 DE DE60112272T patent/DE60112272T2/de not_active Expired - Lifetime
- 2001-04-26 JP JP2001580909A patent/JP3729343B2/ja not_active Expired - Lifetime
- 2001-04-26 WO PCT/JP2001/003649 patent/WO2001083481A1/ja active IP Right Grant
- 2001-04-26 CN CNB018086551A patent/CN1173975C/zh not_active Expired - Lifetime
- 2001-04-26 AU AU2001252609A patent/AU2001252609A1/en not_active Abandoned
- 2001-04-26 EP EP01925980A patent/EP1277754B8/en not_active Expired - Lifetime
- 2001-04-26 ES ES01925980T patent/ES2244613T3/es not_active Expired - Lifetime
- 2001-04-26 CA CA2407573A patent/CA2407573C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1600783A (zh) | 2005-03-30 |
CA2407573C (en) | 2011-09-13 |
CA2407573A1 (en) | 2001-11-08 |
JP3729343B2 (ja) | 2005-12-21 |
DE60112272T2 (de) | 2006-05-24 |
CN1308327C (zh) | 2007-04-04 |
EP1277754B1 (en) | 2005-07-27 |
AU2001252609A1 (en) | 2001-11-12 |
ES2244613T3 (es) | 2005-12-16 |
DK1277754T3 (da) | 2005-11-14 |
EP1277754A1 (en) | 2003-01-22 |
KR100830859B1 (ko) | 2008-05-21 |
CN1426413A (zh) | 2003-06-25 |
EP1277754B8 (en) | 2005-09-28 |
ATE300540T1 (de) | 2005-08-15 |
EP1277754A4 (en) | 2003-06-04 |
DE60112272D1 (de) | 2005-09-01 |
WO2001083481A1 (fr) | 2001-11-08 |
KR20030014206A (ko) | 2003-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1173975C (zh) | 咪唑并吡啶衍生物 | |
CN100345830C (zh) | 稠合杂芳基衍生物 | |
CN1166678C (zh) | 嘌呤衍生物 | |
JP6026441B2 (ja) | キナーゼ阻害剤としてのアミノキノリン | |
CN1271070C (zh) | 用作腺苷A2α受体的配体的三唑基-咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用 | |
CN1294577A (zh) | 钾通道抑制剂 | |
CN1659145A (zh) | 作为egf-r和her2激酶抑制剂的3-氰基喹啉 | |
CN1759114A (zh) | 作为细胞因子抑制剂的杂环n-芳基甲酰胺 | |
JP2020526543A (ja) | ロイシンリッチリピートキナーゼ2の阻害剤 | |
CN1444567A (zh) | 咪唑衍生物 | |
CN1230184A (zh) | 芳氨基稠合的吡啶和嘧啶 | |
CN1867331A (zh) | 作为TNF-α调节剂的沙利度胺类似物 | |
CN1278819A (zh) | 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶 | |
CN101052634A (zh) | 作为vegf受体激酶抑制剂的邻氨基苯甲酰胺吡啶脲 | |
AU2015210593A1 (en) | Compounds | |
CN1551881A (zh) | 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途 | |
CN101031565A (zh) | 取代的2h-1,3-苯并噁嗪-4(3h)-酮 | |
CN1694705A (zh) | 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶 | |
CN1701074A (zh) | 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶 | |
CN1056879A (zh) | 吡咯衍生物及其制备方法 | |
US10858367B2 (en) | Compounds | |
CN1511151A (zh) | 3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物 | |
JP2020506966A (ja) | 化合物 | |
CN1794990A (zh) | 代谢型谷氨酸受体-5的二芳基取代吡咯调节剂 | |
JP2020505399A (ja) | 化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LUDWIG CANCER RESEARCH INST. INC.; CANCER REC TEC Free format text: FORMER OWNER: LUDWIG CANCER RESEARCH INST. INC.; EMPIRE CANCER REC TECH LTD. Effective date: 20050218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20050218 Address after: Tokyo, Japan Co-patentee after: Ludwig Institute for Cancer Research Patentee after: Yamanouchi Pharmaceutical Co., Ltd. Co-patentee after: Cancer Rec Tech Ltd. Address before: Tokyo, Japan Co-patentee before: Ludwig Institute for Cancer Research Patentee before: Yamanouchi Pharmaceutical Co., Ltd. Co-patentee before: Imperial Cancer Research Technology Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: ASTELLAS PHARMA INC.; LUDWIG CANCER RESEARCH INST. Free format text: FORMER NAME OR ADDRESS: YAMANOUCHI PHARMACEUTICAL CO., LTD.; LUDWIG CANCER RESEARCH INST. INC.; CANCER REC TECH LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Tokyo, Japan Co-patentee after: Ludwig Institute for Cancer Research Patentee after: Yamanouchi Pharma Co., Ltd. Co-patentee after: Cancer Rec Tech Ltd. Address before: Tokyo, Japan Co-patentee before: Ludwig Institute for Cancer Research Patentee before: Yamanouchi Pharmaceutical Co., Ltd. Co-patentee before: Cancer Rec Tech Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20041103 |
|
CX01 | Expiry of patent term |